PHARMAZIE 润色咨询

PHARMAZIE

出版年份：1946 年文章数：2432 投稿命中率： 开通期刊会员，数据随心看

出版周期：Monthly 自引率：3.1% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-04-13 bysl

    学长，我私信你了，麻烦看下私信，万分感谢。156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:
    兄弟，你的文章接受了吗？我2月初投的，到现在还没信

    156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2016-11-02 da-xiang

    我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀!

    中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-09-02 susong340826

    这个刊物，是一定要推荐审稿人吗，不推荐会怎么样

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-09-02 susong340826

    这个刊物，是一定要推荐审稿人吗

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-09-03 ms8000001980435671

    这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-05-06 榴莲味少女

    请问现在收到消息了吗？156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:
    兄弟，你的文章接受了吗？我2月初投的，到现在还没信

    156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-04-21 榴莲味少女

    朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。bysl 2020-04-13 00:00:00 发表:
    学长，我私信你了，麻烦看下私信，万分感谢。

    bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-03-20 121703d1m90(暂无昵称)

    兄弟，你的文章接受了吗？我2月初投的，到现在还没信872922461_64325386 2020-01-03 发表::
    请问让选择推荐审稿人的时候是应该怎么选择呀    bysl 2020-01-03 00:00:00 发表:
    请问让选择推荐审稿人的时候是应该怎么选择呀

    872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2020-01-03 bysl

    请问让选择推荐审稿人的时候是应该怎么选择呀182vsoH8609(暂无昵称) 2019-09-15 发表::
    研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。    182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:
    8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。

    182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=588749, encodeId=935f588e49ac, content=学长，我私信你了，麻烦看下私信，万分感谢。<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=115, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Mon Apr 13 00:00:00 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=528912, encodeId=e11d528912c4, content=我也注册了一个，第一次也像你说的，根本没收到邮件。我又重新注册了一个，后面终于到了。感觉要看运气啊~话说这个杂志是哪个国家的呀! <br> <br> 中药也收的，我看了有混合物的药理研究~我也正打算投篇中药的试试。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=322, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/14/2898b376c776c22ab6af859e66faa209.jpg, createdBy=78131975014, createdName=da-xiang, createdTime=Wed Nov 02 19:51:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881969, encodeId=f977881969c3, content=这个刊物，是一定要推荐审稿人吗，不推荐会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:20:26 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881970, encodeId=7b9e8819e0e3, content=这个刊物，是一定要推荐审稿人吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e4e2834124, createdName=susong340826, createdTime=Wed Sep 02 00:22:08 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882372, encodeId=cd868823e276, content=这个杂志不是SCI吗？web of science中才收录到今年4月份的文章！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200614/308143e428c14d0590e9026a1718e0db/9f2eb4c6f2004e4faa879f62538c22b6.jpg, createdBy=56f45379989, createdName=ms8000001980435671, createdTime=Thu Sep 03 08:18:22 CST 2020, time=2020-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590308, encodeId=1c655903083f, content=请问现在收到消息了吗？<span class="quote">156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表:<br>兄弟，你的文章接受了吗？我2月初投的，到现在还没信</span>, beContent=156cHS95990(暂无昵称) 2020-03-20 00:00:00 发表: 兄弟，你的文章接受了吗？我2月初投的，到现在还没信, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Wed May 06 00:00:00 CST 2020, time=2020-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=589383, encodeId=348e589383b0, content=朋友，你的稿件什么时候投的？送审了吗？我看稿件号都有15000多了，这到底是今年投稿量还是创刊以来的投稿量。。<span class="quote">bysl 2020-04-13 00:00:00 发表:<br>学长，我私信你了，麻烦看下私信，万分感谢。</span>, beContent=bysl 2020-04-13 00:00:00 发表: 学长，我私信你了，麻烦看下私信，万分感谢。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ia14wziafLzcAeZ4vYxdTeBibHZ8fp8oSmRkbaMRXlHLQnqq15v5ACJZzGkcb1MHr89mzms77P8P4KkExXaxc3jUQ/132, createdBy=508d2440943, createdName=榴莲味少女, createdTime=Tue Apr 21 00:00:00 CST 2020, time=2020-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587056, encodeId=744858e056b3, content=兄弟，你的文章接受了吗？我2月初投的，到现在还没信<span class="quote">872922461_64325386 2020-01-03 发表::<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span><span class="quote">bysl 2020-01-03 00:00:00 发表:<br>请问让选择推荐审稿人的时候是应该怎么选择呀</span>, beContent=872922461_64325386 2020-01-03 发表:: 请问让选择推荐审稿人的时候是应该怎么选择呀, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4852254650, createdName=121703d1m90(暂无昵称), createdTime=Fri Mar 20 00:00:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582615, encodeId=8df558261556, content=请问让选择推荐审稿人的时候是应该怎么选择呀<span class="quote">182vsoH8609(暂无昵称) 2019-09-15 发表::<br>研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span><span class="quote">182vsoH8609(暂无昵称) 2019-09-15 20:44:00 发表:<br>8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。</span>, beContent=182vsoH8609(暂无昵称) 2019-09-15 发表:: 研究方向：药理;心血管药理学; 接收率：约75% 审稿时间：约1个月 8月11号投的文章，9月10号杂志社直接决定接收文章。个人认为，杂志的要求不高。但是一定要按照杂志社的要求上传手稿。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/07/06aac315efc99ec0fc8a99388573d021.jpg, createdBy=e91e5230762, createdName=bysl, createdTime=Fri Jan 03 00:00:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579877, encodeId=8e095e987710, content=我注册也遇到了问题 请问你是怎么解决的？<span class="quote">139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:<br>请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我</span>, beContent=139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=dsYRaF3Em8WnrfLTazc9iag&s=100&t=1555811525, createdBy=c5535227686, createdName=认真脸盲, createdTime=Thu Nov 14 00:00:00 CST 2019, time=2019-11-14, status=1, ipAttribution=)]
    2019-11-14 认真脸盲

    我注册也遇到了问题 请问你是怎么解决的？139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表:
    请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我

    139FFjd5983(暂无昵称) 2018-05-19 00:00:00 发表: 请问你是怎么注册上的啊?我注册时没有密码自动生成.也没有邮件发给我

    0

共169条页码: 3/17页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分